SCHEMBL949288

SCHEMBL949288

Cc1nc2ccccc2cc1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
HPGD P15428 4/20 0.59
KDM4E B2RXH2 3/20 0.59
GAA P10253 3/20 0.59
STAT3 P40763 2/20 0.59
GLA P06280 2/20 0.52
MAPT P10636 2/20 0.52
ACHE P22303 1/20 0.52
NPC1 O15118 3/20 0.52
KMT2A Q03164 3/20 0.52
RAB9A P51151 2/20 0.52
POLB P06746 2/20 0.52
LMNA P02545 1/20 0.52
PTBP1 P26599 1/20 0.52
RCE1 Q9Y256 1/20 0.52
MEN1 O00255 2/20 0.49
TLR8 Q9NR97 5/20 0.48
CYP1A2 P05177 3/20 0.48
HTR3A P46098 1/20 0.48
TDP1 Q9NUW8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30099865 1.00 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EGAASTAT3
SCHEMBL30285938 1.00 ALDH1A1 (0.59) ALDH1A1HPGDKDM4EGAASTAT3
SCHEMBL29454362 0.77 TLR8 (0.57) ALDH1A1HPGDKDM4EGAAGLA
SCHEMBL359102 0.77 TLR8 (0.57) ALDH1A1HPGDKDM4EGAAGLA
SCHEMBL30486684 0.77 ALDH1A1 (0.63) ALDH1A1HPGDKDM4EGAASTAT3
SCHEMBL422035 0.77 ALDH1A1 (0.63) ALDH1A1HPGDKDM4EGAASTAT3
SCHEMBL17942819 0.77 ALDH1A1 (0.53) ALDH1A1KDM4EGAAMAPTKMT2A
SCHEMBL17942650 0.77 NCK1 (0.57) ALDH1A1HPGDKDM4EMAPTNPC1
Hydrochloric Acid SCHEMBL7361242 0.76 ALDH1A1 (0.61) ALDH1A1HPGDKDM4EGAASTAT3
Bromide SCHEMBL27763629 0.76 ALDH1A1 (0.61) ALDH1A1HPGDKDM4EGAASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 WO disclosed
CN-110603253-B Heteroaryl phenylamino quinolines and analogs 拜耳公司 2023-01-20 CN disclosed
CN-113929662-B Succinimide or maleimide compound and use thereof 中国医学科学院药物研究所 2023-01-06 CN disclosed
CN-113956236-B Phthalimide compound and application thereof 中国医学科学院药物研究所 2023-01-06 CN disclosed
EP-3247692-B1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LTD (IN) 2022-09-07 EP disclosed
CN-109867661-B Amide compounds for regulating WNT signal pathway and application thereof 中国医学科学院药物研究所 2022-07-19 CN disclosed
CN-113956236-A Phthalimide compound and application thereof 中国医学科学院药物研究所 2022-01-21 CN disclosed
CN-113929662-A Succinimide or maleimide compound and use thereof 中国医学科学院药物研究所 2022-01-14 CN disclosed
CN-112912374-A Oxocyclobutylphenoxyquinolines and analogs 拜耳公司 2021-06-04 CN disclosed
CN-110603253-A Heteroaryl phenylamino quinolines and analogs 拜耳公司 2019-12-20 CN disclosed
US-20080032986-A1 BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-02-07 US disclosed
WO-2008006627-A1 BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-01-17 WO disclosed
EP-1878717-A1 Benzyl amines, a process for their production and their use as anti-inflammatory agents Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-16 EP disclosed
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation BIOLIPOX AB (SE) 2007-09-27 US disclosed
EP-1794145-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION Biolipox AB (SE) 2007-06-13 EP disclosed
WO-2006032851-A1 PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2006-03-30 WO disclosed
US-20040171634-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, LLC 2004-09-02 US disclosed
CN-1152015-C Piperazine devivatives and process for preparation thereof ������ҩ��ʽ���� 2004-06-02 CN disclosed
CN-1207729-A Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 (NK-3) and neurokinin 2 (NK-2) receptor antagonists SMITHKLINE BEECHAM SPA (IT) 1999-02-10 CN disclosed
CN-1196724-A Novel piperazine derivative and process for producing the same SAMJIN PHARM CO LTD (KR) 1998-10-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225318-A1 Pyrazole Compounds Useful In The Treatment Of Inflammation ALOX15, ALOX15B, ALOX12 ALDH1A1 306/4885HPGD 66/4885KDM4E 3533/4885
US-20040171634-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, ROCK1 ALDH1A1 2836/4885HPGD 1087/4885KDM4E 2368/4885
US-20080032986-A1 BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS IL1B, BBOX1, TNF ALDH1A1 294/4885HPGD 120/4885KDM4E 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.